Moderna Inc.

Moderna, with partner Merck, announced positive topline Phase 3 results for intismeran (V940/mRNA-4157) combined with Keytruda, meeting the primary endpoint for recurrence-free survival and a key secondary endpoint for distant metastasis-free survival in high-risk melanoma. Moderna says integrated AI algorithms were used to select patient-specific neoantigens for the individualized mRNA therapy. The companies have released only topline data so far, overall survival follow-up continues and intismeran remains investigational pending full data disclosure and regulatory review. The article notes broader AI advances in medicine but emphasizes that many tools are still experimental and require clinical validation. » More on tech.yahoo.com

Moderna reported at the Morgan Stanley Healthcare Conference that the phase III melanoma study of Intismeran showed a statistically significant and clinically meaningful adjuvant benefit versus KEYTRUDA. The company remains committed to its 2028 breakeven target and is expanding its vaccine business to five approved products, including flu/COVID combinations. Moderna highlights manufacturing capacity in Marlborough to enable early market launch, expects staggered oncology data over several years, and still sees open questions on pricing, regulation and commercial potential. » More on de.investing.com

Moderna shares rose about 7.5% in the morning to $146.84, recovering markedly from sell‑offs that had pushed the stock below its 52‑week high. Drivers include a reassessment of the previously negative view from Rothschild & Co Redburn, the Phase‑3 success of the personalized cancer vaccine Intismeran Autogen (together with Merck), and recent US approvals for updated COVID‑19 vaccines and the flu vaccine mFLUSIVA. Additional tailwinds come from a raise by Argus (price target $180), the upcoming presentation at the Morgan Stanley Global Healthcare Conference, and a positive market environment. » More on de.investing.com